More Trials

So I've added a couple more trials to an ever growing list. At last count I've had 12 different regimens over the last 10+ years half of which were clinical trials. There is definitely a "Aren't you special." feedback from all the attention clinical trial patients get.The ABT-199 trial ended after 5 cycles with evidence of progression seen via imaging (PET/CT). I have a tough clone to clobber. Illusive secretive beast that stops expressing any evidence of progression in the blood. Instead it just munches away at my bones with a relentlous incideous appetite.There is no doubt that the Oprozomib trial was not worth the extra attention. The first cycle (2 weeks) was tolerable but the second was a total GI, bedridden disaster with disease progression just to add to the insult. Here's a mouthful for those MM geeks: Oprozomib is an orally-administered epoxyketone proteasome inhibitor, similar to, but distinct from carfilzomib. The current experiment is a Phase I Open label, Dose Escalation Study of I-131-CLR1404. I just happen to be the first MM patient enrolled in this study. Here's the MM geek excerpt from the press release link: "I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted radiopharmaceutical comprised of a proprietary optimized phospholipid ether (PLE) analog, acting as a cancer-targeted delivery and retention vehicle, covalently labeled with iodine-131, a cytotoxic radioisotope that is already commonly used to treat thyroid and other cancer typ...
Source: Laughing Plasma Cells - Category: Cancer & Oncology Source Type: blogs